Skip to main content

Table 2 Frequency of cardiovascular risk factors by dose regimen

From: Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Number of CVRFsa Placebo
N = 1262
n (%)
All LTN
N = 3177
n (%)
Total
N = 4439
n (%)
0 255 (20.2) 684 (21.5) 939 (21.2)
1 486 (38.5) 1181 (37.2) 1667 (37.6)
2 326 (25.8) 837 (26.3) 1163 (26.2)
3 144 (11.4) 357 (11.2) 501 (11.3)
4 43 (3.4) 101 (3.2) 144 (3.2)
5 8 (0.6) 17 (0.5) 25 (0.6)
  1. aCVRFs were based on the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [45] and included age, total and high-density lipoprotein cholesterol, systolic blood pressure (including treated or untreated status), diabetes, and current smoking status
  2. CVRFs Cardiovascular risk factors, LTN Lasmiditan, N number of patients in the analysis population, n number of patients within each specific category